Core Viewpoint - Water Lily Consultants Inc., one of the largest shareholders of the company, has voluntarily committed to extend the lock-up period for its shares until July 2, 2026, indicating confidence in the company's future prospects and recognition of significant progress in the development and commercialization of its candidate drugs [1]. Group 1 - Water Lily holds a total of 158 million shares, representing approximately 18.71% of the total issued shares [1]. - Water Lily has the right to receive 63.1565 million shares under the equity incentive plan, subject to the relevant conditions of those restricted share units [1]. - The board of directors believes that Water Lily's voluntary extension of the lock-up period reflects its confidence in the company's future and acknowledges the positive developments in the group's business [1].

Core Viewpoint - WaterLily Consultants Inc. has voluntarily committed to extend the lock-up period for its shares in the company until July 2, 2026, or an earlier date agreed upon with the company [1] Group 1: Shareholding Information - As of the announcement date, WaterLily holds a total of 157,992,705 shares, representing approximately 18.71% of the total issued shares [1] - WaterLily has also been granted restricted share units that entitle it to receive an additional 63,156,492 shares, subject to certain vesting conditions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. 撥康視雲製藥有限公司 * （於開曼群島註冊成立的有限公司） 本公告乃由撥康視雲製藥有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願發佈，旨在告 知其股東及潛在投資者，本公司單一最大股東已延長禁售期。 茲提述：(a)本公司日期為2025年6月24日的招股章程（「招股章程」）；及(b)本公司日期為2025年7月2 日的配發結果公告（「配發結果公告」）。除文義另有界定外，本文所用詞彙與招股章程所界定者具有 相同涵義。 誠如招股章程及配發結果公告所披露，根據(a)單一最大股東各自向本公司出具的禁售承諾函件（「承 諾函」）及(b)香港包銷協議，單一最大股東已各自承諾（其中包括），除下列情況外：(i)（就承諾函而 言）根據全球發售或股權激勵安排及首次公開發售後股權激勵計劃，或根據上市規則獲准；或(ii)（就 包銷協議而言）事先獲得聯席保薦人及整體 ...

Group 1: Market Movements - Baoji Pharmaceutical-B (02659) surged over 3.2% amid its debut on the Hong Kong Stock Exchange, closing up 138.82% on its first day, with a market capitalization exceeding HKD 20 billion [1] - New Energy (01799) and Xinyi Solar (00968) saw declines of 3.01% and 3.67% respectively, as the photovoltaic sector faced weakness, with rumors of a 30 billion yuan investment for capacity storage by major companies [1] - Xpeng Motors-W (09868) and Li Auto-W (02015) dropped 4.88% and 2.67% respectively, following data from the China Association of Automobile Manufacturers indicating a month-on-month increase in production and sales [1] Group 2: Company-Specific News - Bolek Vision Cloud-B (02592) experienced a significant drop of nearly 15%, having previously doubled in price over 10 trading days, as it announced a new drug trial application to the FDA [2] - Hu Shang Ayi (02589) rose nearly 6% as Nayuki Tea expanded into the U.S. market, enhancing the international presence of Chinese tea brands [2] - Gold stocks fell sharply, with Zijin Mining (02899) and Shandong Gold (01787) declining by 4.29% and 4.94% respectively, following a report on the Bloomberg Commodity Index's upcoming rebalancing [2] Group 3: Cryptocurrency and Technology - Cryptocurrency ETFs faced significant declines, with notable drops in Bitcoin and Ethereum-related funds, as Bitcoin fell 3.3% from its record high, reflecting market pressures amid weak liquidity [3] - Oracle (ORCL.US) continued its downward trend, dropping 2.66% due to delays in delivering AI data centers for OpenAI, attributed to labor and material shortages [6] - Nvidia (NVDA.US) saw a slight increase of 0.73% after announcing the release of its third-generation language model, aimed at writing and programming tasks [6]

Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has experienced significant volatility, with a nearly 15% drop and a more than 40% decline since December 5, following a rapid price increase that saw the stock double in value over just 10 trading days from November 21 to December 4 [1] Company Developments - Bolekang Vision announced that its wholly-owned subsidiary, ADS Therapeutics LLC, submitted a new drug clinical trial application for CBT-199, a potential best-in-class ophthalmic candidate, to the U.S. Food and Drug Administration on December 15 [1] - CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, with expectations that these studies will support future clinical trials [1] - On January 3, two cornerstone investors of Bolekang Vision will face a lock-up expiration for their shares [1]

Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has experienced significant volatility, with a nearly 15% drop and a more than 40% withdrawal since December 5, following a substantial price increase of 100% over just 10 trading days from November 21 to December 4 [1] Group 1: Stock Performance - The stock price is currently down 11.59%, trading at HKD 4.96, with a trading volume of HKD 6.7798 million [1] - The stock saw a remarkable increase in value, doubling within a short span of 10 trading days [1] Group 2: Company Announcements - Bolekang Vision announced that its wholly-owned subsidiary, ADS Therapeutics LLC, submitted a new drug clinical trial application for CBT-199 to the U.S. Food and Drug Administration on December 15 [1] - CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, which are expected to support future clinical trials [1] Group 3: Investor Information - On January 3, two cornerstone investors of Bolekang Vision will face a lock-up expiration for their shares [1]

Company News - China Shenhua (01088.HK) reported coal sales of 389.5 million tons for the first 11 months, a decrease of 7.7% year-on-year. November sales were 37 million tons, down 3.6% year-on-year [1] - China Metallurgical Group (01618.HK) signed new contracts worth RMB 958.13 billion in the first 11 months, an 8.6% decrease year-on-year, with overseas contracts amounting to RMB 75 billion, a 0.4% increase year-on-year [1] - China Eastern Airlines (00670.HK) saw a 6.51% year-on-year increase in passenger capacity in November, with passenger turnover up 10.35% year-on-year and a seat load factor of 87.37%, up 3.04 percentage points year-on-year [1] - China Southern Airlines (01055.HK) reported an 8.68% year-on-year increase in passenger capacity in November, with passenger turnover up 10.42% year-on-year and a seat load factor of 86.29%, up 1.36 percentage points year-on-year [1] - New China Life Insurance (01336.HK) recorded cumulative original insurance premium income of RMB 188.85 billion for the first 11 months, a 16% year-on-year increase [1] - AOS Group (01161.HK) announced annual results for the year ending September 30, 2025, with revenue of approximately HKD 981 million, a decrease of 0.19% year-on-year, and a net profit of HKD 80.887 million, a 19% year-on-year increase [1] - Hopson Development Holdings (00754.HK) reported total contract sales of approximately RMB 14.27 billion for the first 11 months, an 8.91% decrease year-on-year [1] - Agile Group (01813.HK) had a pre-sale amount of RMB 511 million in November, a decrease of 21.4% year-on-year [1] - Galen Pharmaceuticals (01672.HK) is expected to become a best-in-class oral small molecule IL-17 inhibitor, with positive topline results from its Phase I study in the U.S. [1] - Bole Technology (02592.HK) submitted a new drug clinical trial application for CBT-199 to the U.S. FDA [1] - China Supply Chain Industry (03708.HK) signed a strategic cooperation framework agreement with Golden Energy regarding digital assets [1] - Times China Holdings (01233.HK) had its liquidation petition withdrawn [1] - Botai Car Union (02889.HK) received a first project designation notice from a leading domestic new energy vehicle client [1] Buyback Activities - Haijia Medical (06078.HK) plans to repurchase 10% of its issued shares, with a repurchase amount of no less than RMB 300 million [1] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with repurchase prices ranging from HKD 602.5 to HKD 608 [1] - Xiaomi Group (01810.HK) repurchased 7.2 million shares for HKD 302 million, with repurchase prices ranging from HKD 41.78 to HKD 42 [1] Share Cancellation - Pacific Shipping (02343.HK) canceled 23.739 million repurchased shares [2]

Core Viewpoint - The company announced that its wholly-owned subsidiary, ADS Therapeutics LLC, submitted a new drug clinical trial application for CBT-199, a potential best-in-class ophthalmic candidate, to the U.S. Food and Drug Administration (FDA) on December 15, 2025 [1]. Group 1 - The submission of the new drug clinical trial application marks a significant step in the development of CBT-199 [1]. - CBT-199 is being developed as a potential best-in-class treatment in the ophthalmic sector [1].

Core Viewpoint - The company has submitted a New Drug Application (NDA) for CBT-199, a potential best-in-class ophthalmic candidate, to the U.S. Food and Drug Administration (FDA) [1][2] Group 1: Product Development - CBT-199 is a novel topical ophthalmic emulsion designed to treat presbyopia, a common age-related condition where the eye's lens thickens and loses elasticity, leading to a decline in near vision [1] - The formulation utilizes the company's proprietary non-aqueous platform, containing a parasympathomimetic miotic agent that induces pupil constriction to create a pinhole effect, thereby increasing depth of focus and improving near vision [1] - The anhydrous formulation aims to prevent the degradation of active ingredients over time, enhancing drug stability, and features a consumer-friendly multi-dose bottle design with a long shelf life, providing a comfortable and soothing medication experience [1] Group 2: Clinical Trials and Regulatory Process - The drug discovery process for CBT-199 began in China in 2023, with preclinical animal studies assessing safety and tolerability starting in June 2023, which are expected to support future clinical trials [2] - The submission of the NDA marks the first step in the FDA's drug review process and obtaining regulatory approval to initiate clinical trials for CBT-199 [2]

诚如本公司日期为2025年6月24日的招股章程所披露，本集团已于2023年在中国开始 CBT-199的药物发 现过程。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估，有关研究预期将有 助于未来的临床试验。提交新药临床试验申请为美国药管局启动药物审查程序以及取得监管批准以展开 CBT-199的临床试验的第一步。 智通财经APP讯，拨康视云-B(02592)发布公告，于2025年12月15日，本公司全资附属公司ADS Therapeutics LLC向美国食品及药物管理局(美国药管局)提交有关CBT-199(一种由本集团开发的潜在同类 最佳眼科候选药物)的新药临床试验申请(新药临床试验申请)。 CBT-199是一种新型局部眼用乳液，适用于治疗老花眼，而老花眼为常见的年龄相关性病症，患者眼内 晶状体逐渐增厚且失去弹性，导致聚焦近物能力持续衰煺。CBT-199采用本集团专有的非水溶性平台制 剂，含副交感神经性缩瞳剂，透过诱导瞳孔收缩形成针孔效应，增加焦距深度从而改善近距离视力。此 无水配方旨在防止活性成分随时间分解以提升药物稳定性，并采用对消费者友善的自保存多剂量瓶装设 计，具备长效保质期 ...